Head-to-head clinical trials evaluating more than 1600 patients

RMS OPERA I and II study design 3,5

The efficacy and safety of OCREVUS (ocrelizumab) in RMS were studied vs Rebif in 2 double-blind, double-dummy trials evaluating more than 1600 patients for 2 years.

MRI and clinical results vs Rebif

5 key clinical efficacy endpoints 3,5

OCREVUS demonstrated superior clinical results vs Rebif across 5 key endpoints over 2 years.

OCREVUS® (ocrelizumab) Safety profile in RMS studies

OCREVUS safety profile for RMS 2,3

The safety of OCREVUS for RMS was studied in the 2-year controlled OPERA I and II clinical trials and in 3+ years of open-label extension study with no change to the risk-benefit profile since launch.

RMS=relapsing multiple sclerosis.